Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Terminal disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    684 result(s) found for: Terminal disease. Displaying page 8 of 35.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2022-000149-34 Sponsor Protocol Number: CR845-310302 Start Date*: 2023-01-17
    Sponsor Name:Cara Therapeutics, Inc.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Seve...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004372-56 Sponsor Protocol Number: 204837 Start Date*: 2018-07-04
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase 3 randomized, double-blind, active-controlled, parallel-group, multi-center study in hemodialysis participants with anemia of chronic kidney disease to evaluate the efficacy, safety and pha...
    Medical condition: anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-010163-16 Sponsor Protocol Number: 08/0285 Start Date*: 2009-06-05
    Sponsor Name:University College London
    Full Title: Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease
    Medical condition: Active Crohn's disease affecting the ileum
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011406 Crohn's ileitis LLT
    9.1 10058815 Crohn's disease acute episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001550-27 Sponsor Protocol Number: CACZ885A2201 Start Date*: 2006-10-20
    Sponsor Name:Novartis Farmaceútica
    Full Title: Estudio aleatorizado, doble ciego, multicéntrico, controlado con placebo, de grupos paralelos, con búsqueda de dosis, de 12 semanas de duración para evaluar la eficacia, la seguridad, y la tolerabi...
    Medical condition: Artritis reumatoide activa
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000507-86 Sponsor Protocol Number: 201410 Start Date*: 2017-03-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 52-week open-label (sponsor-blind), randomized, active controlled, parallel-group, multi-center study to evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoiet...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002672-13 Sponsor Protocol Number: RH/BARACKD/0003 Start Date*: 2013-04-09
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance Office
    Full Title: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) Trial: a prospective randomised open blinded endpoint trial to determine the effect of aldosterone receptor antagoni...
    Medical condition: We plan a large pragmatic trial to test the potential for spironolactone to to reduce overall cardiovascular events and death, to delay the decline in renal function, and to improve surrogate marke...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10064848 Chronic kidney disease LLT
    15.1 10022891 - Investigations 10018355 Glomerular filtration rate PT
    15.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-003200-39 Sponsor Protocol Number: 13/0077 Start Date*: 2014-04-01
    Sponsor Name:University College London
    Full Title: A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma
    Medical condition: Renal complications of systemic sclerosis (scleroderma renal crisis and chronic kidney disease).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10061087 Connective tissue disorder PT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10018124 Generalized scleroderma LLT
    16.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002610-13 Sponsor Protocol Number: M11-612 Start Date*: 2013-12-06
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hem...
    Medical condition: - Stage 5 chronic kidney disease - Secondary to hyperparathyroidism
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018285-23 Sponsor Protocol Number: 18102009 Start Date*: 2010-06-04
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St.Thomas' NHS Foundation Trust
    Full Title: Effect of active vitamin D treatment on arterial stiffness and albuminuria in patients with type 2 diabetes and stage 3 chronic kidney disease
    Medical condition: Diabetic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10009119 Chronic renal failure LLT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002834-59 Sponsor Protocol Number: SNFCT2015-05 Start Date*: 2016-11-28
    Sponsor Name:Sanifit Therapeutics S.A.
    Full Title: A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patie...
    Medical condition: Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004857 10014646 End stage renal disease (ESRD) LLT
    20.0 10047065 - Vascular disorders 10051753 Vascular calcification PT
    20.0 10042613 - Surgical and medical procedures 10018875 Haemodialysis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003025-10 Sponsor Protocol Number: VIVID Start Date*: 2011-11-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease.
    Medical condition: Left ventricular hypertrophy, type 2 diabetes, chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10007541 - Cardiac disorders 10047295 Ventricular hypertrophy PT
    20.0 100000004861 10012612 Diabetes mellitus non insulin-dep LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001579-35 Sponsor Protocol Number: KBP5074-2-001 Start Date*: 2019-08-07
    Sponsor Name:KBP BioSciences Co., Ltd.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients with Moderate-to-Severe Chronic Kidney Disea...
    Medical condition: Moderate to Severe Chronic Kidney Disease and uncontrolled hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001520-18 Sponsor Protocol Number: NL76839.042.21 Start Date*: 2021-04-09
    Sponsor Name:RECOVAC consortium
    Full Title: Long term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with chronic kidney disease stage G4-G5, on dialysis or after kidney transplantation
    Medical condition: COVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccin...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084464 COVID-19 immunization LLT
    23.1 10042613 - Surgical and medical procedures 10084465 COVID-19 vaccination LLT
    23.1 100000004848 10084508 COVID-19 antibody test LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    23.0 10042613 - Surgical and medical procedures 10084463 SARS-CoV-2 immunisation LLT
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    20.0 10042613 - Surgical and medical procedures 10061105 Dialysis PT
    20.0 10042613 - Surgical and medical procedures 10018875 Haemodialysis PT
    20.0 10042613 - Surgical and medical procedures 10034660 Peritoneal dialysis PT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    23.1 10038359 - Renal and urinary disorders 10076412 Chronic kidney disease stage 5 LLT
    23.1 10038359 - Renal and urinary disorders 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005999-13 Sponsor Protocol Number: D8180C00034 Start Date*: 2008-02-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Open-label, Pilot Study to Evaluate the Safety and the Effects on Bone Resorption of AZD0530 in Patients with Prostate Cancer or Breast Cancer with Metastatic Bone Disease ...
    Medical condition: Prostate Cancer or Breast Cancer with Metastatic Bone Disease Cáncer de próstata o de mama con metástasis óseas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) SE (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006535-53 Sponsor Protocol Number: MCI-196-E08 Start Date*: 2007-08-09
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Multiple Fixed-dose Study of MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphospha...
    Medical condition: Hyperphosphataemia and dyslipidaemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020711 Hyperphosphataemia LLT
    9.1 10058108 Dyslipidaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000829-44 Sponsor Protocol Number: H9X-MC-GBDX Start Date*: 2012-09-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes and Moderate or Severe Chroni...
    Medical condition: Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000547-27 Sponsor Protocol Number: CTIMPMCRENAL12 Start Date*: 2012-11-01
    Sponsor Name:East and North Hertfordshire NHS Trust [...]
    1. East and North Hertfordshire NHS Trust
    2. University of Hertfordshire
    Full Title: A Pilot Randomised Controlled Trial of Drug Treatment for Depression in Patients undergoing Haemodialysis
    Medical condition: Major Depressive Disorder in Patients with End Stage Renal Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    14.1 10042613 - Surgical and medical procedures 10066623 Chronic haemodialysis LLT
    14.1 10038359 - Renal and urinary disorders 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002174-32 Sponsor Protocol Number: REN00304 Start Date*: 2005-01-13
    Sponsor Name:Genzyme Europe BV
    Full Title: An open label, randomized, parallel design study to investigate the efficacy and safety of sevelamer hydrochloride (Renagel®) compared with calcium acetate in peritoneal dialysis patients (REN00304)
    Medical condition: Peritoneal dialysis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10034660 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011000-34 Sponsor Protocol Number: CAIN457F2201 Start Date*: 2009-09-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 16-week multicenter, randomized, double-blind, placebo-controlled, parallel group, dose-finding study to evaluate the efficacy, safety and tolerability of subcutaneous AIN457 followed by an exten...
    Medical condition: Moderate to severe Rheumatoid Arthritis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) BE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-002373-22 Sponsor Protocol Number: 2012-NIGRAM-VUMC-001 Start Date*: 2014-05-12
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: ThE SoF-Trial (SoFT) - The Effect of Sevelamer on FGF23 Trial - A clinical trial assessing the quantitative effect of phosphate binding therapy on FGF23.
    Medical condition: cardiovascular disease in chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 05:11:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA